Heart failure & cardiomyopathiesSecondary analysis
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events
- Post hoc analysis of the SOLOIST-WHF randomised trial
Authors' conclusion
Starting sotagliflozin before discharge in patients with type 2 diabetes hospitalized for WHF significantly decreased cardiovascular deaths and HF events through 30 and 90 days after discharge
Study context
- Population
- Patients with T2DM hospitalised for worsening HF who began study treatment on or before dischargeof 1,222 randomized
- Participants
- 596 patients
- Comparison
- Sotagliflozin vs placebo started on or before discharge
- Primary endpoint
- CV death or HF-related event (HF hospitalization or urgent care visit)
- Follow-up
- 90 and 30 days after discharge
Primary result
As reported in the abstract
CV death or HF-related event
Sotagliflozin vs PlaceboHazard ratio (95% CI)P value
90 days after discharge
0.54(0.35–0.82)
P = 0.00430 days after discharge
0.49(0.27–0.91)
P = 0.023Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortality · 90 days | 0.39 (0.17–0.88) | P = 0.024 | |
| 0.10.31310Hazard ratio (log scale) |
90-day main endpoint by subgroup (sex, age, eGFR, NT-proBNP, LVEF, MRA use)
- Sotagliflozin reduced the 90-day main endpoint regardless of subgroup
Safety
Tolerability, diarrhoea and volume-related events
- Well-tolerated but slightly higher rates of diarrhea and volume-related events than placebo
Original publication
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events. JACC Heart Fail. doi:10.1016/j.jchf.2023.05.026
Summarised from the published abstract; every number is checked against it